AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 2 analysts
Fundamentals
Fundamentals institutional score is 91 using growth durability 90.7.
Valuation
Valuation institutional score is 65 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 69 using mean target upside 18.0%; dispersion penalty 14.7; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 52 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 2 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and valuation provide support, while technical structure and market sentiment remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 4.1% above historical median. Valuation is stable — currently in the overvalued zone (z-score: +0.4). Confidence: 72%.
Live forward EPS implies next-12-month EPS of ₹50.80. Applying the stock's normalized valuation corridor produces a fair range of ₹1,375.66 to ₹2,161.03, with base value near ₹1,874.01 (+94.2% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹50.80
Forward P/E
19.0x
Base Fair Value
₹1,874.01
Fair Range
₹1,375.66 - ₹2,161.03
Upside To Base
+94.2%
Estimate Source
Live forward EPS
Growth Estimate
-45.0%
5Y Average
27.43
Current
38.40
Overvalued
42.54
Undervalued
27.08
5Y Average
1.27
Current
1.77
Overvalued
1.46
Undervalued
1.08
5Y Average
2.48
Current
2.15
Overvalued
2.85
Undervalued
2.11
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 31.2x Fair | -15% vs avg | +25.2% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 28.4x Undervalued | -23% vs avg | +43.2% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 39.9x Fair | +8% vs avg | +51.8% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.6x Premium | +18% vs avg | -23.8% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.7x Fair | -3% vs avg | +9.4% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 38.4x Fair | +4% vs avg | -15.4% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 38.8x Fair | +5% vs avg | +22.5% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Fair | +5% vs avg | +30.0% |
JUBILANT PHARMOVA LTD trades in line with peers (38.4x vs avg 36.8x), reflecting a fair valuation within the Pharmaceuticals cohort. Peers include CAPLIN POINT LAB LTD., ALIVUS LIFE SCIENCES LTD, AKUMS DRUGS AND PHARMA L — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹70 CrMar 2026Latest net profit
₹57 CrMar 2026Latest EPS
₹3.59Mar 2026Net margin
21.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 200 | 217 | 186 | 175 | 206 | 53 | 61 | 56 | 61 | 60 | 66 | 67 | 70 |
| Expenses + | 198 | 213 | 186 | 176 | 194 | 43 | 51 | 46 | 50 | 49 | 55 | 55 | 56 |
| Operating Profit | 2 | 4 | 1 | -1 | 12 | 10 | 10 | 10 | 11 | 10 | 12 | 12 | 14 |
| OPM % | 1.1% | 1.9% | 0.4% | -0.4% | 6% | 18% | 16% | 18% | 18% | 17% | 18% | 18% | 21% |
| Other Income + | 14 | 16 | 18 | 19 | 50 | -14 | 16 | 3 | 13 | 2 | 42 | 0 | -8 |
| Interest | 6 | 6 | 7 | 8 | 8 | 3 | 3 | 3 | 3 | 3 | 2 | 1 | 1 |
| Depreciation | 11 | 11 | 12 | 12 | 13 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| Profit before tax | -1 | 2 | 0 | -2 | 42 | -10 | 21 | 8 | 19 | 8 | 50 | 10 | 4 |
| Tax % | 2,467% | 17% | 300% | 4% | 22% | 5% | 50% | 34% | 30% | 29% | 113% | 35% | -1,295% |
| Net Profit + | -31 | 2 | -0 | -2 | 32 | -10 | 10 | 5 | 14 | 6 | -6 | 7 | 57 |
| EPS in Rs | -1.93 | 0.12 | -0.03 | -0.15 | 2.04 | -0.64 | 0.66 | 0.33 | 0.85 | 0.36 | -0.40 | 0.41 | 3.59 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Postponement And Rescheduling Of Board Meeting Scheduled For August 10, 2026
Newspaper Advertisements Titled ''Notice Of 48Th Annual General Meeting, E-Voting, Record Date And Final Dividend Information